---
document_datetime: 2024-08-28 16:00:40
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ibandronic-acid-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ibandronic-acid-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.0685034
conversion_datetime: 2025-12-17 09:27:47.840104
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Ibandronic Acid Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0022              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 16/08/2024                          |                                             | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0021   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                    | 06/06/2024   | n/a        |                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|
| IB/0020   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 22/11/2022   | 19/12/2023 | SmPC and PL                      |
| N/0019    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                               | 23/07/2021   | 19/12/2023 | PL                               |
| IA/0018   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                  | 07/01/2021   | 23/07/2021 | Annex II and PL                  |
| IB/0017   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                 | 07/08/2020   | 23/07/2021 | SmPC, Annex II, Labelling and PL |
| IB/0016   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 10/11/2016   | 30/10/2017 | SmPC and PL                      |
| IA/0015   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                  | 25/04/2016   | 15/09/2016 | Annex II and PL                  |
| IAIN/0014 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                 | 14/12/2015   | 15/09/2016 | SmPC and PL                      |
| IB/0013/G | This was an application for a group of variations.                                                                                                                                             | 24/09/2015   | 15/09/2016 | SmPC, Annex II, Labelling        |

<div style=\"page-break-after: always\"></div>

|         | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0012  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 23/04/2015 | 25/06/2015 | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Ibandronic Acid Teva continues to be favourable. The CHMP was also of the opinion that the renewal can be granted with unlimited validity. |
| T/0011  | Transfer of Marketing Authorisation from Teva Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                             | 03/11/2014 | 01/12/2014 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0010 | B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold                                                                                                                                                                                                                                                                                                                                                                                                   | 16/04/2014 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IB/0009   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                        | 12/03/2014   | 27/06/2014   | SmPC, Annex II and PL            |             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------|
| IA/0008/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 06/09/2013   | n/a          |                                  |             |
|           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                      | 14/06/2013   | n/a          |                                  | IAIN/0007   |
| IB/0006   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                      | 05/06/2013   | 27/06/2014   | SmPC, Annex II, Labelling and PL |             |
|           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                          | 14/06/2012   | 29/10/2012   | Annex II and PL                  | IAIN/0005/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IB/0004/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 10/01/2012 | n/a | B.I.d.1.a.4 |

<div style=\"page-break-after: always\"></div>

|           | period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                      |            |            |                                  |                                                                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------|
| IB/0003/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for | 20/10/2011 | 10/05/2012 | SmPC, Annex II, Labelling and PL |                                                                |
| IB/0002   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                        | 15/07/2011 | n/a        | SmPC, Annex II, Labelling and PL |                                                                |
| A20/0001  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 19 October 2010, the opinion of the CHMP on measures necessary to ensure the safe use of the above mentioned medicinal product further to the CHMP review on the currently available data in relation to the incidence of atypical stress fractures and its impact on the risk-benefit balance.           | 14/04/2011 | 29/06/2011 | SmPC, Annex II and PL            | Please refer to the Assessment Report: H-1195-RAR-A20- 0001_en |